We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| ALK Abello AS | TG:4AJ0 | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|
| -0.18 | -0.83% | 21.56 | 90 | 22:50:06 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 21.46 | 21.66 | 21.38 | 21.32 | 21.38 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 14:53:53 | 70 | 21.32 | EUR |
| Date | Time | Source | Headline |
|---|---|---|---|
| 20/12/2024 | 16:08 | UKREG | ALK – Financial calendar for the 2025 financial year |
| 18/12/2024 | 11:51 | UKREG | Positive results advance peanut tablet to phase II development |
| 12/12/2024 | 15:06 | UKREG | ACARIZAX® approved in Europe for treatment of young children |
| 27/11/2024 | 12:45 | UKREG | ALK’s pivotal phase 3 trial in children published in reputable scientific.. |
| 14/11/2024 | 06:30 | UKREG | Nine-month interim report (Q3) 2024 (unaudited) |
| 09/11/2024 | 22:29 | UKREG | ALK licenses rights to neffy®, the first approved adrenaline nasal spray.. |
| 07/11/2024 | 11:08 | UKREG | Invitation to the presentation of ALK’s results for the first nine months.. |
| 27/8/2024 | 15:30 | UKREG | Report on transactions with ALK-Abelló A/S B-shares and associated.. |
| 22/8/2024 | 15:49 | UKREG | Six-month interim report (Q2) 2024 |
| 22/8/2024 | 15:38 | UKREG | ALK upgrades its full-year revenue and earnings outlook |
ALK Abello AS (4AJ0) Share Charts1 Year ALK Abello AS Chart |
|
1 Month ALK Abello AS Chart |
Intraday ALK Abello AS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
